Virax Biolabs Group Ltd (VRAX)
About Virax Biolabs Group Ltd
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $1.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.6M
- Shares outstanding
- 494.5K
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 21, 2022
Virax Biolabs Group Ltd (VRAX) Stock Price
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Virax Biolabs Group Ltd.
Write a review
News about Virax Biolabs Group Ltd
News & sentiment via Polygon.io
Virax Biolabs Group Ltd: frequently asked questions
Is Virax Biolabs Group Ltd an American company?
Virax Biolabs Group Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Virax Biolabs Group Ltd publicly traded?
Yes — Virax Biolabs Group Ltd is a publicly traded company. Its stock trades under the ticker symbol VRAX on the NASDAQ.
What does Virax Biolabs Group Ltd do?
Virax Biolabs Group Ltd is an American Medical Devices company in the Health & Beauty sector.
